Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 838 results for score

  1. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

  2. Atrial fibrillation: annual stroke risk assessment (IND127)

    This indicator covers the percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM81

  3. Insertion of endobronchial nitinol coils to improve lung function in emphysema (IPG517)

    Evidence-based recommendations on insertion of endobronchial nitinol coils to improve lung function in emphysema. This involves inserting coils to reduce airflow to damaged parts of the lung.

  4. Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants (IPG412)

    Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).

  5. Photodynamic therapy for brain tumours (IPG290)

    Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.

  6. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

  7. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  8. Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

    Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.

  9. Minimally invasive total hip replacement (IPG363)

    Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.

  10. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

  11. Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)

    Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.

  12. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  13. Transabdominal artificial bowel sphincter implantation for faecal incontinence (IPG276)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

  14. Occipital nerve stimulation for intractable chronic migraine (IPG452)

    Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.

  15. Joint distraction for ankle osteoarthritis (IPG538)

    Evidence-based recommendations on joint distraction for ankle osteoarthritis in adults. This involves fixing a metal frame around the ankle and pulling the joint slightly apart using the frame to allow cartilage regrowth.